586 Topical nitric oxide releasing therapy with 2% SB414 cream downregulated major gene expressions in patients with atopic dermatitis

A Phase 1b, multi-center, randomized, double-blind, vehicle-controlled study was conducted in 48 adult patients with mild-to-moderate atopic dermatitis (AD). 17, and 14 patients received SB414 2% cream, SB414 6% cream and vehicle, respectively, twice daily for 2 weeks. SB414 showed trends suggestive of efficacy based on the change in eczema area severity index (EASI), itch numerical rating score (NRS) and target lesion severity score. Both SB414 2% and 6% were well tolerated, but 2% had a more favorable local tolerability profile with no quantifiable systemic exposure.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Interventional Studies, Clinical and Patient Outcomes Research Source Type: research